Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4650
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$69.68
Last synced: 2026-10-19
Market Cap
$3.26B
Change (1 day)
2.36%
Change (1 year)
-2.13%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
Earnings for Tarsus Pharmaceuticals, Inc. (TARS)
Earnings in Jun 2026 TTM: $-44.05M
According to Tarsus Pharmaceuticals, Inc. latest financial reports the company's current earnings are $-44.05M. In 2023 the company made an earning of $-135.89M, a decrease compared to its 2022 earnings that were of $-62.10M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Tarsus Pharmaceuticals, Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
